Prudhomme Clémence, Joannard Brune, Lina Gérard, De Launay Eleonore, Dumitrescu Oana, Hodille Elisabeth
Laboratoire de Biologie médicale de Référence des Nocardioses, Groupement Hospitalier Nord, Institut des Agents Infectieux, Hospices civils de Lyon, Lyon, France.
Ann Clin Microbiol Antimicrob. 2024 Dec 18;23(1):105. doi: 10.1186/s12941-024-00768-2.
Drug susceptibility testing (DST) for Nocardia spp. is essential to initiate effective antibiotic therapy. Currently, the only recommended technique is the determination of minimum inhibitory concentrations (MICs) by microdilution. This method can be tedious to perform, despite the availability of ready-to-use plates. Herein, the aim was to determine the critical inhibition diameters specific to Nocardia spp.
MICs of 134 Nocardia isolates were determined by microdilution. Interpretative categories (Susceptible/Intermediate/Resistant) were determined using Clinical and Laboratory Standards Institute breakpoints. In parallel, disk diffusion DST was performed. Receiver-operating-characteristic (ROC) curves were constructed to determine the inhibition diameter value that best discriminated between susceptible and non-susceptible strains (intermediate/resistant). The category agreement (CA), the rate of major (maj) and very major (vmj) discrepancies between microdilution and disk diffusion method was calculated.
For tobramycin, the critical diameter of 19 mm (diameter ≤ 19 mm = resistant strain; diameter > 19 mm = susceptible strain) provided a CA of 98.5%, 0.0% vmj, and 2.9% maj discrepancies, reaching strictly the acceptable performance criteria defined by the U.S. Food and Drug Administration (FDA). For amikacin, the critical diameter of 25 mm (diameter ≤ 25 mm = resistant strain; diameter > 25 mm = susceptible strain) provided a CA of 98.5%, 0.0% vmj, and 1.5% maj discrepancies. For imipenem, excluding N. farcinica and N. cyriacigeorgica, the critical diameter of 29 mm (diameter ≤ 29 mm = resistant strain; diameter > 29 mm = susceptible strain), provided a CA of 98.6%, 0.0% vmj, and 0.0% maj discrepancies. Despite an estimated vmj rate 0.0%, the 95%-confident-interval exceeded the FDA criteria due to an insufficient number of amikacin/imipenem-resistant strains. For other tested antibiotics (ciprofloxacin, moxifloxacin, amoxicillin-clavulanate, ceftriaxone, cotrimoxazole, linezolid), the FDA criteria were not reached.
Although the FDA criteria were mostly unmet, disk diffusion DST was suitable to accurately categorize Nocardia isolates into interpretative categories for the aminoglycosides and imipenem only, excluding species N. farcinica and N. cyriacigeorgica.
诺卡菌属的药敏试验(DST)对于启动有效的抗生素治疗至关重要。目前,唯一推荐的技术是通过微量稀释法测定最低抑菌浓度(MIC)。尽管有即用型平板,但这种方法操作起来可能很繁琐。在此,目的是确定诺卡菌属特有的临界抑菌直径。
通过微量稀释法测定134株诺卡菌分离株的MIC。使用临床和实验室标准协会的断点确定解释类别(敏感/中介/耐药)。同时,进行纸片扩散法药敏试验。构建受试者工作特征(ROC)曲线以确定最能区分敏感和不敏感菌株(中介/耐药)的抑菌直径值。计算微量稀释法和纸片扩散法之间的类别一致性(CA)、主要(maj)和非常主要(vmj)差异率。
对于妥布霉素,临界直径为19毫米(直径≤19毫米=耐药菌株;直径>19毫米=敏感菌株),CA为98.5%,vmj差异率为0.0%,maj差异率为2.9%,严格达到美国食品药品监督管理局(FDA)定义的可接受性能标准。对于阿米卡星,临界直径为25毫米(直径≤25毫米=耐药菌株;直径>25毫米=敏感菌株),CA为98.5%,vmj差异率为0.0%,maj差异率为1.5%。对于亚胺培南,排除嗜皮诺卡菌和乔治亚那嗜油诺卡菌后,临界直径为29毫米(直径≤29毫米=耐药菌株;直径>29毫米=敏感菌株),CA为98.6%,vmj差异率为0.0%,maj差异率为0.0%。尽管估计vmj率为0.0%,但由于阿米卡星/亚胺培南耐药菌株数量不足,95%置信区间超过了FDA标准。对于其他测试抗生素(环丙沙星、莫西沙星、阿莫西林-克拉维酸、头孢曲松、复方新诺明、利奈唑胺),未达到FDA标准。
尽管大多未达到FDA标准,但纸片扩散法药敏试验仅适用于将诺卡菌分离株准确分类为氨基糖苷类和亚胺培南的解释类别,不包括嗜皮诺卡菌和乔治亚那嗜油诺卡菌。